Related Experiment Videos
Long-term thymopentin treatment in systemic scleroderma
C Danese1, E Zavattaro, L Calisi
1Clinica Medica II, Università degli Studi di Roma La Sapienza, Italy.
Current Medical Research and Opinion
|January 1, 1994
Summary
Thymopentin treatment for systemic scleroderma significantly reduced specific lymphocytes (CD16+, CD25+) and improved clinical symptoms in most patients. This suggests thymopentin can positively impact immune balance and disease progression.
Area of Science:
- Immunology
- Rheumatology
- Clinical Medicine
Background:
- Systemic scleroderma is an autoimmune disease characterized by immune dysregulation.
- Investigating immunomodulatory therapies is crucial for managing scleroderma.
- Thymopentin is a thymic peptide with known immunomodulatory properties.
Purpose of the Study:
- To evaluate the effect of thymopentin on immunological status in systemic scleroderma patients.
- To correlate immunological changes with clinical condition modifications.
- To assess the long-term impact of thymopentin therapy.
Main Methods:
- Nine systemic scleroderma patients received intravenous thymopentin for 5 weeks, repeated every 3 months for 1-5 years.
- Lymphocytic sub-populations (CD16+, CD25+) were analyzed pre- and post-treatment cycles.
- Clinical condition was assessed throughout the follow-up period.
- A control group of healthy subjects was included for comparison.
Main Results:
- A statistically significant decrease in CD16+ and CD25+ lymphocytes was observed after the first treatment cycle.
- Seven out of nine patients showed clinical improvement by the end of the follow-up.
- Thymopentin treatment led to a significant correction of imbalanced lymphocytic subsets.
Conclusions:
- Thymopentin treatment can induce significant changes in lymphocyte populations in systemic scleroderma patients.
- These immunological modifications correlate with clinical improvements.
- Thymopentin shows potential as a therapeutic agent for systemic scleroderma.